<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04693247</url>
  </required_header>
  <id_info>
    <org_study_id>EYEQUE - 004</org_study_id>
    <nct_id>NCT04693247</nct_id>
  </id_info>
  <brief_title>Handheld Device Compared With a Standard Eye Care Diagnostic Device in Measuring Ophthalmic Refraction</brief_title>
  <official_title>An Exploratory Study in Healthy Adult Volunteers to Evaluate the Best Corrected Visual Acuity (BCVA) Performance of a Handheld Device Compared With a Standard Eye Care Diagnostic Device in Measuring Ophthalmic Refraction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EyeQue Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EyeQue Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is exploratory and examines whether the best-corrected visual acuities (BCVA's)&#xD;
      from trial frames created with the refraction results obtained from a novel handheld optical&#xD;
      device yields results similar to the ophthalmic refraction obtained from an autorefractor in&#xD;
      healthy volunteers age stratum of 18 through 65 years.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is exploratory and examines whether the best-corrected visual acuities (BCVA's)&#xD;
      from trial frames created with the refraction results obtained from a novel handheld optical&#xD;
      device yields results similar to the ophthalmic refraction obtained from an autorefractor in&#xD;
      healthy volunteers age stratum of 18 through 65 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 28, 2020</start_date>
  <completion_date type="Anticipated">October 15, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Tester and subject for BCVA are masked as to which device and trial frames are from.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Best corrected visual acuity (BCVA) for both eyes EQ103 vs Autorefractor for all participants</measure>
    <time_frame>Day 1</time_frame>
    <description>Tendency of, or achieving, statistical non-inferiority of EyeQue EQ103 BCVA's (reading an EDTRS chart) for each eye from (pooled) trial frames created with the refraction values compared with those of an autorefractor analyzed with all age groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Best corrected visual acuity (BCVA) for both eyes EQ103 vs Autorefractor examining age groupings</measure>
    <time_frame>Day 1</time_frame>
    <description>Tendency of, or achieving, statistical non-inferiority of EyeQue EQ103 BCVA's (reading an EDTRS chart for each eye (pooled) from trial frames created with the refraction values compared with those of an autorefractor analyzed within the following age strata.&#xD;
o Age Groups: 18 - 29, 30 - 44, 45 - 65</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best corrected visual acuity (BCVA) for worse eye: EQ103 vs Autorefractor for all subjects and age groupings</measure>
    <time_frame>Day 1</time_frame>
    <description>Tendency of, or achieving, statistical non-inferiority of EyeQue EQ103 BCVA's (reading an EDTRS chart for worse eye from trial frames created with the refraction values compared with those of an autorefractor analyzed within the following age strata.&#xD;
o Age Groups: All, 18 - 29, 30 - 44, 45 - 65</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Refractive Errors</condition>
  <condition>Vision Disorders</condition>
  <arm_group>
    <arm_group_label>Refraction with a Hand-held Refraction Device</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This is the device that will be compared to a standard device.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Autorefractor</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Standard Device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EQ103</intervention_name>
    <description>Refraction device</description>
    <arm_group_label>Autorefractor</arm_group_label>
    <arm_group_label>Refraction with a Hand-held Refraction Device</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or Female&#xD;
&#xD;
          -  Ages =&gt;18 y.o. and =&lt;65 y.o.&#xD;
&#xD;
          -  Binocular vision&#xD;
&#xD;
          -  Willing and able to give informed consent and follow all study procedures and&#xD;
             requirements&#xD;
&#xD;
          -  Fluent in English&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has been diagnosed within 4 weeks, or currently has signs or symptoms, of COVID-19.&#xD;
&#xD;
          -  Has traveled outside the country within the last 4 weeks.&#xD;
&#xD;
          -  At the discretion of the investigator: Age strata has achieved minimum evaluable&#xD;
             population.&#xD;
&#xD;
          -  Spherical correction &gt; +8 or &lt; -10&#xD;
&#xD;
          -  Using anticholinergic medications (including first-generation antihistamines) or other&#xD;
             medications known to affect visual acuity within the greater of 3 days or 5 half-lives&#xD;
             prior to enrolling in this study&#xD;
&#xD;
          -  Using an investigational drug or approved therapy for investigational use within the&#xD;
             greater of 3 days or 5 half-lives prior to enrolling in this study&#xD;
&#xD;
          -  Has initiated any new medication in the past 2 weeks that, in the best medical&#xD;
             judgment of the investigator, would impact their participation in the study or ability&#xD;
             to use the EyeQue EQ103 device&#xD;
&#xD;
          -  Any self-reported mental illness or condition, including but not limited to:&#xD;
&#xD;
        claustrophobia, fear of simulators, nyctophobia.&#xD;
&#xD;
          -  Any self-reported neurological diseases, including but not limited to: epilepsy,&#xD;
             Alzheimer's, nystagmus&#xD;
&#xD;
        Per subject self-reporting: eye disease, including but not limited to:&#xD;
&#xD;
          -  Glaucoma&#xD;
&#xD;
          -  Cataracts&#xD;
&#xD;
          -  Macular degeneration&#xD;
&#xD;
          -  Eye infection (by self-report or observation)&#xD;
&#xD;
          -  Keratoconus&#xD;
&#xD;
          -  Diabetic neuropathy/retinopathy&#xD;
&#xD;
          -  Cytomegalovirus retinitis&#xD;
&#xD;
          -  Color blindness (any color deficiency)&#xD;
&#xD;
          -  Diabetic macular edema&#xD;
&#xD;
          -  Amblyopia&#xD;
&#xD;
          -  Chronic or acute uveitis&#xD;
&#xD;
          -  Strabismus&#xD;
&#xD;
          -  Astigmatism &gt; 3 diopters&#xD;
&#xD;
          -  Macular hole&#xD;
&#xD;
        Subjects that:&#xD;
&#xD;
          -  Lack physical dexterity to properly operate the EyeQue device.&#xD;
&#xD;
          -  Lack the ability to follow instruction&#xD;
&#xD;
          -  Lack a command of the English language&#xD;
&#xD;
          -  Lack binocular vision&#xD;
&#xD;
          -  Are colorblind&#xD;
&#xD;
          -  Had eye surgery within the last 12 months (including Lasik)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>EyeQue</name>
      <address>
        <city>Newark</city>
        <state>California</state>
        <zip>94560</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul TANPIENGCO</last_name>
      <phone>510-455-8168</phone>
      <email>paul.tanpiengco@eyeque.com</email>
    </contact>
    <investigator>
      <last_name>Noam Sapiens, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 29, 2020</study_first_submitted>
  <study_first_submitted_qc>December 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 5, 2021</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vision Disorders</mesh_term>
    <mesh_term>Refractive Errors</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

